Cargando…
Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
There are limited data concerning the immunogenicity and reactogenicity of COVID-19 vaccines in children. A total of 110 children, 5–11 years old were vaccinated with two doses (with a 3-week interval between doses) of the Pfizer-BioNTech COVID-19 vaccine and were followed for 21, 90, and 180 days a...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693260/ https://www.ncbi.nlm.nih.gov/pubmed/36423049 http://dx.doi.org/10.3390/vaccines10111954 |
_version_ | 1784837494473228288 |
---|---|
author | Joseph, Gili Klein, Elisheva Lustig, Yaniv Weiss-Ottolenghi, Yael Asraf, Keren Indenbaum, Victoria Amit, Sharon Kriger, Or Gilboa, Mayan Levy, Yuval Pessach, Itai M. Kreiss, Yitshak Regev-Yochay, Gili Stein, Michal |
author_facet | Joseph, Gili Klein, Elisheva Lustig, Yaniv Weiss-Ottolenghi, Yael Asraf, Keren Indenbaum, Victoria Amit, Sharon Kriger, Or Gilboa, Mayan Levy, Yuval Pessach, Itai M. Kreiss, Yitshak Regev-Yochay, Gili Stein, Michal |
author_sort | Joseph, Gili |
collection | PubMed |
description | There are limited data concerning the immunogenicity and reactogenicity of COVID-19 vaccines in children. A total of 110 children, 5–11 years old were vaccinated with two doses (with a 3-week interval between doses) of the Pfizer-BioNTech COVID-19 vaccine and were followed for 21, 90, and 180 days after vaccination for immunogenicity, adverse events, and breakthrough infections. Ninety days after the first vaccine dose, the GeoMean (CI 95%) of IgG ascended to 1291.0 BAU (929.6–1790.2) for uninfected children and 1670.0 BAU (1131.0–2466.0) for Infected children. One hundred and eighty days after receiving the first dose of the vaccine, the titers decreased to 535.5 BAU (288.4–993.6) for the uninfected children, while only a small decline was detected among infected children—1479.0 (878.2–2490.0). The neutralizing antibodies titer almost did not change over time in the uninfected children, and even elevated for the infected children. Of the 110 vaccinated children, 75.5% were infected, with only mild COVID-19 infection symptoms. Child vaccination was found to be safe, with mild, mostly local, and of short duration, reported AEs. No serious adverse events (SAEs) were reported after vaccination. The durability of two doses of vaccine in children is longer, thus a booster may not be needed as early as in adults. |
format | Online Article Text |
id | pubmed-9693260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96932602022-11-26 Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years Joseph, Gili Klein, Elisheva Lustig, Yaniv Weiss-Ottolenghi, Yael Asraf, Keren Indenbaum, Victoria Amit, Sharon Kriger, Or Gilboa, Mayan Levy, Yuval Pessach, Itai M. Kreiss, Yitshak Regev-Yochay, Gili Stein, Michal Vaccines (Basel) Article There are limited data concerning the immunogenicity and reactogenicity of COVID-19 vaccines in children. A total of 110 children, 5–11 years old were vaccinated with two doses (with a 3-week interval between doses) of the Pfizer-BioNTech COVID-19 vaccine and were followed for 21, 90, and 180 days after vaccination for immunogenicity, adverse events, and breakthrough infections. Ninety days after the first vaccine dose, the GeoMean (CI 95%) of IgG ascended to 1291.0 BAU (929.6–1790.2) for uninfected children and 1670.0 BAU (1131.0–2466.0) for Infected children. One hundred and eighty days after receiving the first dose of the vaccine, the titers decreased to 535.5 BAU (288.4–993.6) for the uninfected children, while only a small decline was detected among infected children—1479.0 (878.2–2490.0). The neutralizing antibodies titer almost did not change over time in the uninfected children, and even elevated for the infected children. Of the 110 vaccinated children, 75.5% were infected, with only mild COVID-19 infection symptoms. Child vaccination was found to be safe, with mild, mostly local, and of short duration, reported AEs. No serious adverse events (SAEs) were reported after vaccination. The durability of two doses of vaccine in children is longer, thus a booster may not be needed as early as in adults. MDPI 2022-11-18 /pmc/articles/PMC9693260/ /pubmed/36423049 http://dx.doi.org/10.3390/vaccines10111954 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Joseph, Gili Klein, Elisheva Lustig, Yaniv Weiss-Ottolenghi, Yael Asraf, Keren Indenbaum, Victoria Amit, Sharon Kriger, Or Gilboa, Mayan Levy, Yuval Pessach, Itai M. Kreiss, Yitshak Regev-Yochay, Gili Stein, Michal Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years |
title | Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years |
title_full | Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years |
title_fullStr | Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years |
title_full_unstemmed | Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years |
title_short | Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years |
title_sort | real-world immunogenicity and reactogenicity of two doses of pfizer-biontech covid-19 vaccination in children aged 5–11 years |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693260/ https://www.ncbi.nlm.nih.gov/pubmed/36423049 http://dx.doi.org/10.3390/vaccines10111954 |
work_keys_str_mv | AT josephgili realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT kleinelisheva realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT lustigyaniv realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT weissottolenghiyael realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT asrafkeren realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT indenbaumvictoria realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT amitsharon realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT krigeror realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT gilboamayan realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT levyyuval realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT pessachitaim realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT kreissyitshak realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT regevyochaygili realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years AT steinmichal realworldimmunogenicityandreactogenicityoftwodosesofpfizerbiontechcovid19vaccinationinchildrenaged511years |